Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

🌐 Medical Xpress (Isle of Man) —
Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

AI Summary

Research examines the benefits and risks of SGLT2 inhibitors for people aged 80 and older who have chronic kidney disease. The findings are scheduled to be presented at ASN Kidney Week 2026, held October 22–25.

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.

Health SGLT2 inhibitors chronic kidney disease older adults kidney research ASN Kidney Week

Read original source →